Glenmark Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Glenmark Pharmaceuticals heeft een totaal eigen vermogen van ₹84.5B en een totale schuld van ₹17.8B, wat de schuld-eigenvermogensverhouding op 21.1% brengt. De totale activa en totale passiva bedragen respectievelijk ₹152.4B en ₹67.9B. De EBIT Glenmark Pharmaceuticals is ₹26.1B waardoor de rentedekking 9.2 is. Het heeft contanten en kortetermijnbeleggingen van ₹18.2B.

Belangrijke informatie

21.1%

Verhouding schuld/eigen vermogen

₹17.81b

Schuld

Rente dekkingsratio	9.2x
Contant	₹18.20b
Aandelen	₹84.45b
Totaal verplichtingen	₹67.90b
Totaal activa	₹152.35b

Recente financiële gezondheidsupdates

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Mar 22

Recent updates

Unpleasant Surprises Could Be In Store For Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) Shares

Feb 09

Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Dec 17

Lirafit Launch And BeiGene Partnership Set To Accelerate Revenue Growth And Market Share

Dec 10 Upcoming biosimilar launches and strategic oncology partnerships could significantly boost Glenmark's revenue and market share in India.

Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

Oct 26

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Sep 21

Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Sep 06

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 06

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Dec 07

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 28

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

May 28

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Mar 22

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Feb 14

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Oct 12

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 21

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 29

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

Jun 04

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹90.3B ) GLENMARK } overtreffen de korte termijn passiva ( ₹61.8B ).

Langlopende schulden: De kortetermijnactiva GLENMARK ( ₹90.3B ) overtreffen de langetermijnschulden ( ₹6.1B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: GLENMARK heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van GLENMARK is de afgelopen 5 jaar gedaald van 59.7% naar 21.1%.

Schuldendekking: De operationele kasstroom van GLENMARK is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: De rentebetalingen op de schuld van GLENMARK worden goed gedekt door EBIT ( 9.2 x dekking).

Balans

Ontdek gezonde bedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/04/14 06:49
Aandelenkoers aan het einde van de dag	2025/04/11 00:00
Inkomsten	2024/12/31
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Glenmark Pharmaceuticals Limited wordt gevolgd door 55 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
null null	Anand Rathi Shares and Stock Brokers Limited
Sriraam Rathi	Anand Rathi Shares and Stock Brokers Limited
Ganeshram Jayaraman	Avendus Spark

Glenmark Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Recent updates

Glenmark Pharmaceuticals Limited Announces Retirement of V.S. Mani, Global Chief Financial Officer, Effective May 26, 2025

Glenmark Pharmaceuticals Inc., USA Launches Vancomycin Hydrochloride for Injection USP, 750 Mg/Vial, 1.25 G/Vial and 1.5 G/Vial ( Single-Dose Vial)

Glenmark Therapeutics Inc., USA Launches Polyethylene Glycol 3350, Powder for Solution, 17 Grams/Capful (OTC)

Third quarter 2025 earnings released: EPS: ₹12.33 (vs ₹16.66 loss in 3Q 2024)

Glenmark Pharmaceuticals Limited Announces Committee Changes, Effective Date Is February 15, 2025

Unpleasant Surprises Could Be In Store For Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) Shares

Glenmark Pharmaceuticals Limited to Report Q3, 2025 Results on Feb 14, 2025

Glenmark Pharmaceuticals Inc., USA Launches Phytonadione Injectable Emulsion USP, 10 Mg/Ml Single Dose Ampules

Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Lirafit Launch And BeiGene Partnership Set To Accelerate Revenue Growth And Market Share

Second quarter 2025 earnings released: EPS: ₹12.55 (vs ₹7.10 loss in 2Q 2024)

Glenmark Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024

Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

Glenmark Pharmaceuticals Limited Approves Dividend for the Year Ended March 31, 2024

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Dividend of ₹2.50 announced

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2024

Price target increased by 13% to ₹1,382

First quarter 2025 earnings released: EPS: ₹12.06 (vs ₹5.31 in 1Q 2024)

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 14, 2024

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Price target increased by 9.7% to ₹1,056

Full year 2024 earnings: EPS and revenues miss analyst expectations

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24

Glenmark Pharmaceuticals Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

Glenmark Pharmaceuticals Limited to Report Q4, 2024 Results on May 24, 2024

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Now 24% overvalued after recent price rise

Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) (GPL).

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Price target increased by 11% to ₹907

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Third quarter 2024 earnings released: ₹16.66 loss per share (vs ₹9.66 profit in 3Q 2023)

Glenmark Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Glenmark Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 10, 2023

Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-Morbidities

Glenmark Pharmaceuticals Receives ANDA Approval for Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg

Nirma Limited entered into a definitive agreement to acquire 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR 56.5 billion.

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals Divests 75% in GLS to Nirma

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals Limited Announces Management Promotions

Upcoming dividend of ₹2.50 per share at 0.3% yield

Insufficient new directors

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2023

ChrysCapital Still in Race to Buy Controlling Stake in Glenmark Life Sciences

Price target increased by 12% to ₹689

First quarter 2024 earnings released: EPS: ₹5.31 (vs ₹6.82 in 1Q 2023)

Glenmark Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 11, 2023

Nirma, Sekhmet Pharmaventures Reportedly Vie for $731 Million Glenmark Life Stake

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Miller Law LLC and Motley Rice LLC Announce a Proposed Settlement in re Zetia (Ezetimibe) Antitrust Litigation

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Full year 2023 earnings released: EPS: ₹10.53 (vs ₹33.37 in FY 2022)

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2022-23

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Third quarter 2023 earnings released: EPS: ₹9.66 (vs ₹7.86 in 3Q 2022)

Glenmark Pharmaceuticals Limited Launches in India Unique I.V. Injection Formulation

Glenmark Pharmaceuticals Launches the Sacubitril + Valsartan Tablets in India for the Treatment of Heart Failure

Glenmark Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 10, 2023

Glenmark Pharmaceuticals Limited Receives Final Approval by United States Food & Drug Administration for Nicardipine Hydrochloride Capsules, 20 Mg and 30 Mg

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Razel Franchise For India And Nepal Region from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR3.1 billion.